title: Clinicopathologic variables and survival comparison of patients with synchronous endometrial and ovarian cancers versus primary endometrial cancer with ovarian metastasis.
abstract: OBJECTIVE
  To determine the clinicopathologic variables and survival in the patients with synchronous endometrial and ovarian cancer (synchronous group) compared to the patients with primary endometrial cancer with ovarian metastasis (metastatic group).
  
  
  METHODS
  The medical records of 423 endometrial cancer patients who received primary surgery were reviewed. Fourteen patients were diagnosed as synchronous group while 49 patients were diagnosed as metastatic group.
  
  
  RESULTS
  The median age in synchronous group was significantly younger than metastatic group (47 versus 56 years). More nulliparous and premenopausal patients were demonstrated in synchronous group. Synchronous group had significantly higher incidence of low grade tumor and lower incidence of deep myometrial invasion. All patients in synchronous group presented in stage I endometrial cancer. Moreover, most patients (85.7%) presented in early stage ovarian cancer and only 14.3% in advanced stage ovarian cancer. Synchronous group had better disease free survival (DFS) and overall survival (OS) than metastatic group. Estimated 5 years DFS was 64.2% versus 41.5%, (P = 0.17) and 5 years OS was 92.8% versus 48.5% (P = 0.036).
  
  
  CONCLUSIONS
  The patients in synchronous group were younger, more nulliparous and had a better prognosis than the patients in the metastatic group.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
authors.forename: Shina
authors.initials: S
authors.lastname: Oranratanaphan
authors.forename: Tarinee
authors.initials: T
authors.lastname: Manchana
authors.forename: Nakarin
authors.initials: N
authors.lastname: Sirisabya
mesh_terms: D000328:Adult; D000368:Aged; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D011336:Probability; D011379:Prognosis; D012042:Registries; D012189:Retrospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D013785:Thailand